MeiraGTx (NASDAQ:MGTX – Get Rating) had its price target cut by investment analysts at Chardan Capital from $47.00 to $41.00 in a report issued on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock.
Separately, Royal Bank of Canada dropped their price objective on shares of MeiraGTx from $27.00 to $22.00 and set an “outperform” rating on the stock in a report on Wednesday.
MeiraGTx Stock Performance
NASDAQ:MGTX opened at $5.41 on Thursday. The firm’s 50-day moving average is $7.33 and its 200-day moving average is $7.30. MeiraGTx has a 52-week low of $5.34 and a 52-week high of $15.16. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.14 and a current ratio of 2.14. The company has a market cap of $262.28 million, a price-to-earnings ratio of -1.89 and a beta of 1.44.
Institutional Trading of MeiraGTx
MeiraGTx Company Profile
MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. It focuses on inherited retinal diseases, neurodegenerative diseases, and severe forms of xerostomia. It operates through the following geographical segments: United States, Ireland, Netherlands, and United Kingdom. Its pipeline includes AAV CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1 and AAV-UPF1.
- Get a free copy of the StockNews.com research report on MeiraGTx (MGTX)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.